Actinogen Medical (ATGGF) AI Stock Analysis

Actinogen Medical

(Other OTC:ATGGF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Positive equity cushionPositive equity and a larger asset base provide Actinogen with some financial cushion while it develops its pipeline. This does not offset the losses, but it offers a stronger starting position for funding clinical programs and managing obligations than a balance sheet already in deficit.

Negative Factors

Revenue collapseThe decline to zero revenue represents a major weakening in top-line generation and reduces the company’s ability to support operations through internally generated income. Unless revenue resumes or a development milestone produces funding, reliance on capital markets is likely to remain important.

Actinogen Medical (ATGGF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $113.51M
Dividend Yield: ―
Average Volume (3M): 51.69K
Price to Earnings (P/E): -8.8
Beta (1Y): 915.86
Revenue Growth: ―
EPS Growth: 3.03%
Country: US
Employees: 6
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Actinogen Medical Business Overview & Revenue Model

Company Description

Actinogen Medical Limited is an Australian biotechnology company dedicated to developing treatments for neurological and neuropsychiatric disorders linked to imbalanced brain cortisol levels. Their lead product, Xanamem, an inhibitor of the 11ß-HSD1...

Actinogen Medical Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

ATGGF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AU:NEU	74Outperform	AUD 2.58B	128.62	6.03%	0.74%	-68.00%	-86.31%
AU:ZLD	52Neutral	AUD 5.95M	-1.56	80.84%	―	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AU:ATH	44Neutral	AUD 60.72M	-2.40	-48.25%	―	―	-16.21%
AU:ENP	43Neutral	AUD 50.66M	-13.48	-63.60%	―	―	29.55%

* Healthcare Sector Average

Performance Comparison

ATGGF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
ATGGF	Actinogen Medical Limited	0.03	0.00	16.00%
AU:ENP	Tryptamine Therapeutics Limited	0.03	-0.01	-18.42%
AU:NEU	Neuren Pharmaceuticals Limited	20.36	-0.44	-2.10%
AU:ATH	Alterity Therapeutics Ltd.	0.27	-0.23	-47.00%
AU:ZLD	Zelira Therapeutics Ltd.	0.50	0.15	42.86%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Actinogen Medical AI Stock Analysis